JGBs Fall, Tracking Declines in U.S. Treasurys
JGBs fall in the morning Tokyo session, tracking Friday’s price declines in U.S. Treasurys. Market participants are likely to ...
Pharmaceutical Technology9h
BMS-986484 by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.
Pharmaceutical Technology10h
Zolacabtagene autoleucel by Bristol-Myers Squibb for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.
New Trump Administration Near. Is Palantir Stock A Buy Or Sell Amid High Valuation?
PLTR stock has jumped 340% in 2024 with much of the gain coming after Trump's election win amid views government AI ...
Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025
Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...
Targeted Oncology15h
The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers
The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...